898 10 archive 2 disk0/00/00/08/98 2007-10-19 13:49:01 2007-10-29 19:06:44 2007-10-19 13:49:01 article show Eid M. Mafauzy Mohamed mafauzy@kb.usm.my Faridah A.R. Universiti Sains Malaysia, School of Medical Sciences, Dept. of Chemical Pathology Universiti Sains Malaysia, School of Medical Sciences, Dept. of Medicine pub R none Glycaemic Control, Type 2 Diabetes Mellitus Two hundred and eleven (211) patients with type 2 diabetes mellitus who were on treatment and monitored for complications at the Outpatient Diabetes Clinic in Hospital Universiti Sains Malaysia, Kubang Kerian between 2001 – 2002 were selected for the study. A structured questionnaire was administered to obtain their medical and family history. Physical examination was performed and fasting venous blood sample was collected for plasma glucose and A1C analysis. Of the total 211 patients, only 4 % were on diet treatment alone, 37% of them were on mono therapy while 59 % were on combination of therapies. Fasting plasma glucose (FPG) > 7.2 mmol/L and glycated hemoglobin (A1C) levels ³ 7% were observed in 60 % and 73 % of type 2 diabetic patients, respectively. Glycated hemoglobin level of 28% of the subjects were < 7%; 36% were between 7 – 9% and 36% were more than 9%. The worst glycaemic control was observed in Malay patients. A1C of Malay and non-Malay subjects were 8.7 ± 2.3 % and 7.7 ± 1.7 %, respectively. Younger patients (age group < 50 years) had significantly higher mean A1C than elderly patients. Duration of diabetes had a clear influence on glycaemic level. Patients with recently diagnosed diabetes (duration of disease < 5 years) had the best glycaemic control. In this study a large proportion of the patients had poor glycaemic control. The variables with significant effects on glycaemic control were ethnicity, age and duration of diabetes mellitus. Better treatment strategies and methods should be used to improve diabetes control and to reduce long-term complications of diabetes. 2003-07 published Malaysian Journal of Medical Sciences 10 2 School of Medical Sciences, Kubang Kerian, Universiti Sains Malaysia 40-49 TRUE 1394195X http://www.medic.usm.my/publication/mjms/ 1. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Mitch, W., Smith S.C., & Sowers J.R. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134 – 1146. 2. Mafauzy M., Mokhtar N., Wan Muhamad W.B., & Musalmah M. Diabetes mellitus and associated cardiovascular risk factors in North-East Malaysia. Asian-Pacific J Public Health 1999; 11 (1): 16 – 19. 3. Public Health Institute, Ministry of Health Malaysia. Report of the Second National Health and Morbidity Survey Conference 1997: 81 – 89. 4. Bloomgarden Z.T. International Diabetes Federation meeting (type 2 diabetes: its prevalence, causes, and treatment). Diabetes Care 1998; 21 (5): 860 – 865. 5. Kuusisto J., Mykkanen L., Pyorala K., & Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43:960 – 967. 6. Van der Does F.E.E., Neeling J.N.D., Snoek F.J., Grootenhuis P.A., Kostense P.J., Bouter L.M., & Heine R.J. Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes (Effects on well-being at 1 year). Diabetes Care 1998; 21 (12): 2085 – 2093. 7. Herman W.H. Glycaemic control in diabetes. BMJ 1999; 319: 104 – 106. 8. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993; 329(14): 977 – 986. 9. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS33). Lancet 1998; 352: 837 – 853. 10. Bunn H.F. Nonenzymatic glycosylation of protein: relevance to diabetes. Am J Med 1981; 70: 325 – 330. 11. Jovanovic L. & Peterson C.M. The clinical utility glycosylated hemoglobin. Am J Med 1981; 70: 331 338. 12. Nathan D.M, Singer D.E., Hurxthal K., & Goodson The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310 (6): 341-346. 13. Cefalu W.T., Wang Z.Q., Bell-Farrow A., Kiger F.D., Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 1994;(7):1317 – 1321. 14. Goldstein D.E., Little R.R., Lorenz R.A., Malone Nathan D., & Peterson C.M. Tests of glycemia diabetes. Diabetes Care 1995; 18 (6): 896 – 909. 15. American Diabetes Association. Standards of Medical Care for Patients With Diabetes Mellitus (Position Statement). Diabetes Care 2002; 25 (1): 213 – 229. 16. Mohamad M., Arshad F., Mohd Noor M.I., & Ali R. Prevalence of dyslipidaemia in non-insulin-dependent diabetic patients attending armed forces clinics in Kuala Lumpur. Asia Pacific J Clin Nutr 1997; 6 (3):203 – 206. 17. Valle T., Koivisto V.A., Reunanen A., Kangas T., & Rissanen, A. Glycemic control in patients with diabetes in Finland. Diabetes Care 1999; 22 (4): 575 – 579. 18. Miller C.D., Phillips L.S., Tate M.K., Porwoll J.M., Rossman S.D., Cronmiller N., & Gebhart S.S.P. Meeting American Diabetes Association Guidelines in Endocrinologist Practice. Diabetes Care 2000; 23 (4):444 – 448. 19. Ismail I.S., Nazaimoon W., Muhamad W., Letchuman R., Singaraveloo M., Hew F.L., Shuguna C., & Khalid B.A.K. Ethnicity and glycaemic control are major determinants of diabetic dyslipidaemia. Diabetic Medicine 2001; 18: 501 – 508. 20. Östgren C.J., Lindblad U., Ranstam J., Melander A, & Råstam L. Glycaemic control, disease duration and b cell function in patients with type 2 diabetes in a Swedish community. Skaraborg hypertension and diabetes project. Diabetic Medicine 2002; 19: 125 –129.